COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER

被引：0
|
作者：
Guan, X. [1 ]
Li, H. C. [1 ]
Xia, Y. [2 ]
Yang, Q. [2 ]
Ma, A. X. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Peoples R China
[2] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE197
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of pertuzumab plus trastuzumab for advanced HER2-positive breast cancer in Brazil: A public health system perspective
    Carvalho, Adriana C.
    Vasconcelos, Vivian C. A.
    Sasse, Andre D.
    CANCER RESEARCH, 2018, 78 (04)
  • [42] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [43] Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab
    Conte, B.
    Fabi, A.
    Poggio, F.
    Blondeaux, E.
    Dellepiane, C.
    D'Alonzo, A.
    Staiano, A.
    Buono, G.
    Arpino, G.
    Magri, V.
    Naso, G.
    Presti, D.
    Mura, S.
    Fontana, A.
    Cognetti, F.
    Molinelli, C.
    Pastorino, S.
    Bighin, C.
    Lambertini, M.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
  • [45] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [46] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
  • [47] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [48] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [49] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [50] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE FOR ADJUVANT TREATMENT OF ADULT PATIENTS WITH HER2+EARLY BREAST CANCER IN TURKEY
    Ersoy, Akyol B.
    Erdogan-Ciftci, E.
    Yanik, L.
    Guler, B.
    Ozcan, G.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
12345